| | |

Second Treatment Course May Increase Mesothelioma Patient Survival

ByHolly Zink

Second Treatment Course May Increase Mesothelioma Patient SurvivalOncologists report that a second treatment course may be a good option for some mesothelioma patients. Almost all mesothelioma patients experience progression after the first treatment. Recommendations for a second treatment are still unclear. There is very limited information available on second and repeat treatments.

Pemetrexed combined with platinum-based chemotherapy is a standard first treatment for mesothelioma. A report in BMC Cancer says that a repeat treatment may be good for eligible patients.

In this study, patients who received a second treatment of chemotherapy survived longer.

Understanding Second Treatments or Retreatments

Malignant pleural mesothelioma is a rare, aggressive cancer linked to asbestos exposure. There have been several recent treatment advances. But the mesothelioma prognosis is still poor with an average survival of one year. Only 10% of patients survive longer than five years.

The standard treatment approach for malignant pleural mesothelioma is surgery and chemotherapy. Unfortunately, most patients are not eligible for surgery. Palliative chemotherapy is often the only possible strategy.

Pemetrexed combined with platinum-based chemotherapy is the standard first treatment option. A clinical trial has also shown the benefit of the addition of bevacizumab.

Despite progress, almost all mesothelioma patients experience cancer progression after the first treatment. There is limited information on the second and later treatments available for patients.

Evaluating Later Treatment Options

Patients who have a good response rate from the first treatment are often offered more. This study evaluated second and repeat treatments with pemetrexed-based chemotherapy.

The research team analyzed 57 patients from two Polish oncological hospitals. These patients were all treated for advanced mesothelioma between 2013 and 2019. Patients were an average of 64 years old.

In the first treatment, 55 patients received pemetrexed-based chemotherapy. Twelve patients received a second treatment. Seven of these received pemetrexed-based chemotherapy.

Patients with a repeat treatment of pemetrexed-based chemotherapy survived 4.5 months longer.

Drawing Conclusions

Malignant mesothelioma patients who have a good response from the first treatment and survive longer than 6 months should be offered a repeat treatment.

The option of retreatment could be a good option when no other treatments are available. These results support other studies in this area.

Retreatment with the same chemotherapy type may be a good option. Especially if the first treatment was a pemetrexed/platinum combination. And particularly whenever no alternative therapy is available.

Source

Ziółkowska, Barbara, Bożena Cybulska-Stopa, Dimitrios Papantoniou, and Rafał Suwiński. “Systemic treatment in patients with malignant pleural mesothelioma–real life experience.” BMC cancer 22, no. 1 (2022): 1-8. https://link.springer.com/article/10.1186/s12885-022-09490-8

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…